Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Oncothyreon -- Ignore unavailable to you. Want to Upgrade?

To: StockMiser who wrote (764)	5/16/1999 5:01:00 PM
From: Bill on the Hill	Respond to of 2344

OH SURE!! Like that would happen. There is not a chance Christie was with you. She has been with me. Jeez dude!!

To: StockMiser who wrote (764)	5/16/1999 11:29:00 PM
From: Silver Knife	Read Replies (1) \| Respond to of 2344

Well we made it on the Dow Jones Newswire today. Hopefully this is a lead in for tomorrow: May 16, 1999 Dow Jones Newswires DJ Biomira: Theratope May Boost Survival After Transplant Dow Jones Newswires ATLANTA -- Biomira Inc. (BIOM) said a study suggests that treatment with its Theratope cancer vaccine following autologous stem cell transplant can increase survival and decrease relapse in ovarian and breast cancer patients compared to the transplant procedure alone. In a press release Saturday, Biomira said 40 cancer patients were treated with high-dose chemotherapy followed by autologous/syngenic stem cell transplantation, with 26 of the patients also receiving five doses of Theratope. All treatments took place between Sept. 1, 1995, and Nov. 18, 1997. Biomira said the chance of death was more than two times greater among control group patients than in patients receiving Theratope. The chance of relapse was about 1.7 times as high in the control group as in vaccinated patients. Biomira develops vaccines and diagnostic tests for cancer.